The signature supports the role of APOE in lipid regulation through apolipoproteins and inflammation and includes, among others, neutrophil secreted granule proteins CAMP, CTSG, DEFA3, and MPO that point to inhibition of OLFM4 as a target for Alzheimer's disease therapeutics. The gene discussed is MPO; the disease is early-onset autosomal dominant Alzheimer disease.